Committee Composition

Share this on: delicious Digg Facebook LinkedIn Twitter Yahoo! Buzz What is this?

	Audit	Nominating and Corporate Governance	Compensation
Steven R. Deitcher , MD
President & Chief Executive Officer Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Hana Biosciences in August 2007. Dr. Deitcher originally joined Hana as Executive Vice President of Development and Chief Medical Officer in May 2007. From 2004 until he joined Hana, Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 15 years of experience as a practicing physician in hematology, medical oncology and vascular medicine. Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special coagulation laboratory. Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and the International Society on Thrombosis and Hemostasis, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 185 journal papers, abstracts and book chapters and has made more than 35 scientific conference presentations. He was the founding editor-in-chief of the journal Current Hematology Reports. Holdings: 20,000 shares     View Transactions Date Type Shares Traded Price Range Dec 31, 2007 Buy 5,000 1.10 Dec 27, 2007 Buy 5,000 1.03 Dec 26, 2007 Buy 5,000 1.07 Dec 24, 2007 Buy 5,000 1.08 May 21, 2007 Statement of Ownership 0 n/a
Andrew K. Ferrer
Associate, Warburg Pincus Andrew K. Ferrer became a director at Talon Therapeutics in June 2010. Mr. Ferrer joined Warburg Pincus in 2009 and is a member of the HealthCare Group which focuses on investments in biotechnology and pharmaceuticals, healthcare services and medical devices. Prior to joining Warburg Pincus, he worked at Berkshire Partners and Goldman Sachs, where he was in the Private Equity Group. Mr. Ferrer received an A.B. from Princeton University's Woodrow Wilson School of Public and International Affairs and an M.B.A. from Harvard Business School.
Howard Furst, MD, MBA
Partner, Deerfield Management Howard Furst, MD, MBA, became a director at Talon Therapeutics in December 2009. Dr. Furst has over 20 years of experience in the healthcare industry and is currently a partner at Deerfield Management. He joined Deerfield Management in 2007 to work on structured transactions in Deerfield's Private Design and Special Situations Funds. Prior to joining Deerfield Management in 2007, Dr. Furst was a portfolio manager for the healthcare group at Magnetar Capital, an investment fund, from 2006 to 2007. Prior to joining Magnetar Capital, Dr. Furst was a principal at Maverick Capital, an investment firm, where he was primarily responsible for managing the firm's investments in the pharmaceutical and biotechnology sectors. Dr. Furst received his M.D. from the New York University School of Medicine, an M.B.A. with a dual concentration in finance and healthcare administration from the Wharton School of Business at the University of Pennsylvania, and a B.A. from the University of Pennsylvania. Dr. Furst also serves as a director of Eclat Pharmaceuticals, New American Therapeutics, and as a director and Chief Medical Officer of NitroMed, Inc., a privately-held specialty pharmaceutical company.
Jonathan S. Leff
Managing Director, Warburg Pincus Jonathan S. Leff became a director at Talon Therapeutics in June 2010. Mr. Leff joined Warburg Pincus in 1996. He is a member of the HealthCare Group and leads the firm's investment efforts in biotechnology and pharmaceuticals. Prior to joining Warburg Pincus, he was a consultant at Oliver, Wyman & Co. Mr. Leff received an A.B. in government from Harvard University and an M.B.A. from the Stanford University Graduate School of Business. Mr. Leff is also a director of Allos Therapeutics, Inspire Pharmaceuticals, InterMune, Rib-X, and ZymoGenetics. Mr. Leff also serves on the Board of Directors of the Biotechnology Industry Organization, and he serves as chairman of the Medical Industry Group of the National Venture Capital Association. In addition, Mr. Leff is a director of the Spinal Muscular Atrophy Foundation and a member of the Executive Committee of the Board of Visitors of Columbia University Medical Center.
Paul V. Maier
Independent Financial Consultant Since November 2009, Mr. Maier has served as Chief Financial Officer of Sequenom, Inc., a publicly held life sciences company. Prior to joining Sequenom, Mr. Maier was an independent financial consultant from 2007-2009. From 1992-2007, Mr. Maier served as Senior Vice President, Chief Financial Officer of Ligand Pharmaceuticals, Inc., a publicly-held biopharmaceutical company based in San Diego, CA. Prior to joining Ligand, Mr. Maier served as Vice President, Finance at DFS West, a division of DFS Group, L.P., a private multinational retailer. Previously, Mr. Maier held various positions in finance and administration at ICN Pharmaceuticals, Inc., a pharmaceutical and biotechnology research products company, and its subsidiary SPI Pharmaceuticals. Mr. Maier currently serves as a director on the boards of Pure Bioscience, Inc. and International Stem Cell Corp., both publicly-held companies. Mr. Maier received an M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University. Holdings: 7,000 shares     View Transactions Date Type Shares Traded Price Range Jun 18, 2008 Buy 7,000 0.75 Mar 13, 2008 Statement of Ownership 0 n/a
Leon Rosenberg , MD
Professor of Molecular Biology, Princeton University Leon E. Rosenberg, M.D., a director of Talon Therapeutics since February 2004, has been a Professor in the Princeton University Department of Molecular Biology and the Woodrow Wilson School of Public and International Public Affairs since 1997. Since 1999, he has also been Professor Adjunct of Genetics at Yale University School of Medicine. From 1997 to 1998, Dr. Rosenberg served as Senior Vice President, Scientific Affairs of Bristol-Myers Squibb Company, and from 1991 to 1997, Dr. Rosenberg served as President of the Bristol-Myers Squibb Pharmaceutical Research Institute, where he was responsible for the company's worldwide pharmaceutical research and development. Prior to Bristol-Myers Squibb, Dr. Rosenberg was Dean of the Yale University School of Medicine from 1984 to 1991.
Robert Spiegel, M.D., FACP
Robert J. Spiegel, MD, FACP became a director at Talon Therapeutics in July 2010. Dr. Spiegel has over 25 years of executive-level pharmaceutical development and product commercialization experience with Schering-Plough. Until his retirement in November 2009, Dr. Spiegel held the position of Chief Medical Officer at Schering-Plough and was a member of their Pharmaceutical Leadership Board and Corporate Licensing Review Board; he was also Chairman of Schering-Plough's Safety Review Board and Preparedness Response Committee (Crisis Control). While with Schering-Plough, Dr. Spiegel was involved in the filing of over thirty NDA submissions and interacted with US FDA and EU regulatory authorities on a regular basis, serving on the executive committees overseeing all research projects and drug licensing activities. He also served as the lead Schering-Plough representative in numerous joint venture development projects with biotechnology and other large pharmaceutical partnerships. Dr. Spiegel originally joined Schering-Plough as Director, Clinical Research, progressing through clinical operations as Vice President, Clinical Research, Senior Vice President, Worldwide Clinical Research, becoming Chief Medical Officer in 1998. Prior to joining Schering-Plough, Dr. Spiegel was Assistant Professor, Department of Medicine, NYU Medical Center. Dr. Spiegel received his undergraduate degree, cum laude, from Yale University and his MD from the University of Pennsylvania. Dr. Spiegel also serves on the Boards of Geron Corporations and Capstone Therapeutics.
Cecilia Gonzalo
Managing Director, Warburg Pincus Cecilia Gonzalo, is a Managing Director at Warburg Pincus LLC and a General Partner of Warburg Pincus & Co., where she focuses on healthcare investments in the biotechnology, pharmaceuticals and healthcare services sectors. Prior to joining Warburg Pincus in 2001, Ms. Gonzalo worked at Goldman Sachs in the Investment Banking Division focusing on corporate finance and mergers and acquisitions transactions in Latin America, as well as in the Principal Investment Area focusing on investments in the region. Ms. Gonzalo received a B.A., cum laude, in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School. Ms. Gonzalo also serves as a director of LaVie Care Centers (formerly known as Florida Healthcare Properties) and Rib-X Pharmaceuticals.

Stock transaction information provided by EDGAR Online. Hana Biosciences, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Investors

Stock Information

Shareholder Tools

Search IR